PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”), today released the first animal efficacy data for its novel lead drug compound, PhGalpha1, a selective inhibitor of Protein Kinase C-alpha (PKC-alpha).
PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”), today released the first animal efficacy data for its novel lead drug compound, PhGalpha1, a selective inhibitor of Protein Kinase C-alpha (PKC-alpha).